First-half 2024 revenue of €6.5 million, organic growth of 20%

Spineway, a specialist in innovative implants for the treatment of severe spine disorders, continued its entirely organic growth (no change in scope) in the second quarter of 2024, recording revenue of €3.4 million. This good performance brings half-year revenue to €6.5 million, representing growth of 20% compared with H1 2023. As a reminder, organic growth was 12% in H1 2023,1 reflecting the Group’s positive trajectory.